Evidence map›Paper›PMID 39899167›Full record

ArticleInternational journal of clinical oncology2025

Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.

Kosuke Ueda, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Taishi Hirano, Hirofumi Kurose, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kosuke UedaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan. ueda_kousuke@med.kurume-u.ac.jp.ORCID http://orcid.org/0000-0002-8154-6616
Naoki ItoDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Yuya SakaiDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Satoshi OhnishiDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Taishi HiranoDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Hirofumi KuroseDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Katsuaki ChikuiDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Keiichiro UemuraDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Kiyoaki NishiharaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Makoto NakiriDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Shigetaka SuekaneDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Tsukasa IgawaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmuno-oncology (IO) combination therapies, including IO + IO or IO + vascular endothelial growth factor targeted therapies (VEGF-TT), have become the standard first-line treatment for advanced renal cell carcinoma (RCC). However, the optimal regimen for patients without prior nephrectomy remains unclear.

methodsData from 99 patients with advanced RCC without nephrectomy, treated with VEGF-TT, IO + IO, or IO + VEGF-TT between May 2008 and May 2024, were retrospectively reviewed and analyzed. Patients were divided into VEGE-TT, IO + IO, and IO + VEGF-TT groups based on their first-line treatment, and survival and tumor response were compared.

resultsAll patients included in this study were categorized as either intermediate or poor risk according to the International Metastatic RCC Database Consortium risk classification. Among the 99 included patients, 41 initiated first-line therapy with VEGF-TT, 36 with IO + IO, and 22 with IO + VEGF-TT. The objective response rates were 17.5% for VEGF-TT, 38.9% for IO + IO, and 61.9% for IO + VEGF-TT. Notably, the IO + VEGF-TT group showed the greatest shrinkage of target kidney lesions (p = 0.0042). In multivariate analyses, bone metastasis (hazard ratio (HR) = 1.812, 95% confidence interval (CI) 1.017-3.228, p = 0.0436) and the first-line regimen (VEGF-TT vs IO + VEGF-TT: HR = 0.129, 95% CI 0.045-0.369, p = 0.0001) were independent prognostic factors for progression-free survival. The first-line regimen (VEGF-TT vs IO + VEGF-TT: HR = 0.303, 95% CI 0.104-0.879, p = 0.0279) independently affected overall survival.

conclusionIO combination therapy, especially IO + VEGF-TT, has demonstrated a higher anti-tumor response in patients with advanced RCC without nephrectomy and may also be highly effective against primary renal tumors. Therefore, further studies are needed to improve patient survival and validate efficacy of IO combination therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNephrectomyRetrospective StudiesTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor AImmune checkpoint inhibitorsImmuno-oncology combination therapiesRenal cell carcinomaTargeted kidney lesions

Identifiers

PMID39899167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.